10-Q: Horizon Space II to Merge with SL Bio

Horizon Space Acquisition II Corp. announced a definitive business combination agreement with SL Bio Ltd., a cellular and gene therapy developer, while facing significant liquidity challenges.

Summary

• Horizon Space Acquisition II Corp. (HSPT), a Special Purpose Acquisition Company (SPAC), entered into a definitive business combination agreement with SL Bio Ltd. on May 9, 2025.
• SL Bio Ltd. is a Cayman Islands exempted company focused on developing groundbreaking cellular and gene therapies through its Taiwan subsidiary, SL Bio Co., Ltd.
• Upon completion of the business combination, both Horizon Space II and SL Bio will become wholly-owned subsidiaries of PubCo, with PubCo Ordinary Shares expected to be listed and traded on the Nasdaq Stock Market LLC.
• The company reported a net income of $693,874 for the six months ended June 30, 2025, primarily driven by $1,456,519 in interest and dividend income from investments held in the Trust Account.
• Formation and operating costs for the six months ended June 30, 2025, significantly increased to $762,645.
• As of June 30, 2025, cash on hand was $26,030, a substantial decrease from $646,720 at December 31, 2024.
• The company reported a working capital deficit of $311,770 as of June 30, 2025, a deterioration from a working capital surplus of $450,875 at December 31, 2024.
• The Trust Account held $70,801,049 as of June 30, 2025, invested in U.S. government treasury bills or money market funds.
• The company has a deadline of November 18, 2025, to complete a business combination, or it will be required to liquidate.

Sentiment

Score: 4

Explanation: While a business combination agreement has been secured, which is a positive step for a SPAC, the explicit 'going concern' warning due to a significant working capital deficit and reliance on sponsor loans introduces substantial financial uncertainty. The positive interest income from the trust account is offset by increasing operating costs and dwindling cash outside the trust.

Positives

• Secured a definitive business combination agreement with SL Bio Ltd., a company operating in the high-growth cellular and gene therapy sector.
• Generated significant interest and dividend income of $1,456,519 from the Trust Account for the six months ended June 30, 2025, contributing to a net income of $693,874.
• The Trust Account holds a substantial balance of $70,801,049, providing a significant asset base and a floor for public shareholder redemptions.

Negatives

• Management has identified "substantial doubt" about the company's ability to continue as a going concern due to its working capital deficit and need for additional financing.
• The company reported a working capital deficit of $311,770 as of June 30, 2025, a significant deterioration from a surplus of $450,875 at December 31, 2024.
• Cash on hand decreased sharply to $26,030 as of June 30, 2025, from $646,720 at December 31, 2024.
• Significant increase in formation and operating costs to $762,645 for the six months ended June 30, 2025, compared to $11,106 in the prior year period.
• Reliance on the Sponsor for working capital loans, with a recent $300,000 promissory note issued to cover liquidity needs.

Risks

• Inability to successfully complete the proposed business combination with SL Bio Ltd. within the required timeframe.
• Proceeds deposited in the Trust Account could become subject to claims of the company's creditors, potentially having priority over public shareholders' claims.
• Failure to complete a business combination within the required 12-month period (or up to 18 months if extended) will result in the company's liquidation and redemption of public shares, with rights expiring worthless.
• Geopolitical conflicts (e.g., Russia/Ukraine, Hamas/Israel) may materially and adversely affect the company's ability to consummate a business combination or the operations of a target business.
• Increased market volatility or decreased market liquidity may impact the ability to raise necessary equity and debt financing.
• Insufficient funds available to operate the business prior to the initial business combination if cost estimates are inaccurate or interest income from the Trust Account is less than expected.
• The company may need to obtain additional financing to consummate the business combination or if a significant number of public shares are redeemed.
• Substantial doubt exists about the company's ability to continue as a going concern due to its working capital deficit and reliance on additional financing.

Future Outlook

The company expects to complete its business combination with SL Bio Ltd., which will result in both entities becoming subsidiaries of PubCo, with PubCo Ordinary Shares listed on Nasdaq. The company anticipates incurring significant professional and transaction costs in pursuit of this combination and will need to secure additional financing to cover working capital needs, especially if a significant number of public shares are redeemed. The deadline for completing a business combination is November 18, 2025, unless extended.

Management Comments

• "Management has determined that these conditions [working capital deficit, need for additional financing] raise substantial doubt about the Company’s ability to continue as a going concern."
• "Management’s plan in addressing this uncertainty is through the Working Capital Loans from our Sponsor or its affiliates."
• "There is no assurance that the Company’s plans to consummate a Business Combination will be successful within the Combination Period."

Industry Context

This filing details a SPAC's progress towards a de-SPAC transaction. The target, SL Bio Ltd., operates in the cellular and gene therapy sector, a high-growth, high-innovation area within biotechnology. SPACs provide an alternative path to public markets for private companies, often in emerging or specialized industries. The current market for de-SPACs has been challenging, with increased redemptions and scrutiny, making successful completion and post-merger performance uncertain.

Comparison to Industry Standards

• The company's cash position outside the trust account is very low, leading to a significant working capital deficit and a "going concern" warning, which is a red flag compared to well-capitalized operating companies.
• The reliance on sponsor loans for working capital is typical for SPACs, but the explicit "substantial doubt" about going concern highlights a more precarious liquidity situation than many peers.
• The interest income generated from the trust account is a positive, reflecting the current interest rate environment, which benefits SPACs holding cash in trust.
• The announced business combination with SL Bio Ltd. positions the company in the competitive and capital-intensive cellular and gene therapy industry. Success will depend on SL Bio's pipeline, clinical progress, and market adoption, which are not detailed in this filing.

Corporate Governance

Related Party Transactions

• The Sponsor acquired 1,725,000 Founder Shares for $25,000 on July 26, 2024.
• The Sponsor transferred 60,000 Founder Shares to independent director nominees and 10,000 to the Chief Financial Officer on August 2, 2024.
• A promissory note agreement was entered into on July 25, 2024, where the Sponsor agreed to loan the Company up to $500,000 for IPO expenses (not drawn as of June 30, 2025).
• An amount of $254,484 is due to the Sponsor for advancements made to cover formation and IPO expenses.
• On July 5, 2025, the Company issued an unsecured promissory note for $300,000 to the Sponsor for additional working capital, which was funded on July 7, 2025, and is convertible into private placement units.
• The Company pays an affiliate of the Sponsor $10,000 per month for administrative support services, though full payment was waived on February 5, 2025.

Stakeholder Impact

• Shareholders: Public shareholders face uncertainty regarding the completion of the business combination and potential redemptions. The 'going concern' warning adds risk to the shares not subject to redemption. The value of rights is contingent on the business combination.
• Sponsor: Continues to provide financial support through loans and advancements, indicating commitment but also increasing its exposure. Its Founder Shares and Private Units are subject to lock-up and specific voting/redemption rights.
• SL Bio Ltd.: The target company stands to gain public market access through the business combination.
• Creditors: The filing notes that proceeds in the Trust Account could become subject to creditor claims, potentially having priority over public shareholders.

Next Steps

• Complete the business combination with SL Bio Ltd.
• PubCo Ordinary Shares are expected to be listed and traded on the Nasdaq Stock Market LLC following the consummation of the SL Bio Business Combination.
• Potentially secure additional financing to meet working capital needs or if significant redemptions occur.
• Address the going concern uncertainty, likely through working capital loans from the Sponsor.

Key Dates

Recommendation

While the company has secured a business combination agreement, a critical step for a SPAC, the explicit 'substantial doubt' about its ability to continue as a going concern due to a significant working capital deficit and reliance on sponsor loans presents a material risk. The trust account provides a floor for public shareholders, limiting downside for those who can redeem, but the operational liquidity outside the trust is precarious. The success of the de-SPAC transaction and the future performance of the combined entity (SL Bio Ltd.) are highly uncertain. Investors should monitor the progress of the business combination and the company's liquidity closely.

Keywords

SPAC, Horizon Space Acquisition II, SL Bio, Business Combination, Cellular Therapy, Gene Therapy, 10-Q, Quarterly Report, Nasdaq, Trust Account, Going Concern, De-SPAC